Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis

DOI Web Site 1 Citations
  • Kaiming Tao
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA
  • Philip L. Tzou
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA
  • Sergei L. Kosakovsky Pond
    Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, USA
  • John P. A. Ioannidis
    Departments of Medicine and of Epidemiology and Population Health and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
  • Robert W. Shafer
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA
  • Takamasa Ueno
    editor

Description

<jats:p>Monoclonal antibodies (MAbs) targeting the SARS-CoV-2 spike protein are among the most effective measures for preventing and treating COVID-19. However, SARS-CoV-2 Omicron variants contain many mutations in their spike receptor-binding domains, the target of all authorized MAbs.</jats:p>

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top